Please read before exploring Peptide Insights
Important: The information on this website is intended for educational and research purposes only.
Peptide Insights provides information about peptides based on published scientific research and clinical literature. This content is designed to help you understand the science, not to guide personal medical decisions.
By continuing, you confirm that you are accessing this information for educational purposes and understand that it does not constitute medical advice.
Ozempic · Wegovy · GLP-1 Agonist
The breakthrough GLP-1 agonist for sustainable weight loss
Typical Dose
0.5–2.4 mg per week
Route
Subcutaneous
Frequency
Once weekly
Cycle
Ongoing (chronic use)
You have almost certainly heard of Semaglutide — it is the active ingredient in Ozempic and Wegovy. It works by mimicking a hormone your gut naturally releases after you eat, called GLP-1. That hormone tells your brain you are full and tells your pancreas to manage blood sugar. Semaglutide does the same thing, but lasts much longer in your body. The result is that people feel full sooner, eat less, and lose significant weight. It is one of the most studied and prescribed medications in the world right now.
Semaglutide activates GLP-1 receptors in three key places. In your brain, it dials down appetite and cravings. In your pancreas, it helps release insulin when blood sugar is high (and stops the hormone that raises blood sugar). In your stomach, it slows down how fast food moves through, which keeps you feeling full longer. All three effects work together to reduce how much you eat and how your body handles the calories you do consume.
Typical Dose
0.5–2.4 mg per week
Dose Range
0.25 mg (starting) to 2.4 mg (maintenance)
Frequency
Once weekly
Route
Subcutaneous injection
Cycle Length
Ongoing (chronic use)
CLINICAL NOTES
Dose is titrated up slowly over 16–20 weeks to minimize GI side effects. Must be prescribed by a physician.
IMPORTANT DISCLAIMER
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol. Individual responses vary and medical supervision is recommended.
GLP-1 agents are typically run solo or with metabolic support peptides. Avoid stacking with other appetite suppressants.
BPC-157 can help mitigate the GI side effects (nausea, gastroparesis) common with semaglutide.
Tesamorelin targets visceral fat specifically while semaglutide drives overall weight loss — a powerful metabolic combination.
AOD-9604's fat-burning mechanism complements semaglutide's appetite suppression for enhanced body composition.
Real experiences from the Peptide Insights community
Have experience with Semaglutide?
Log in to share your experience and help the community.
No reviews yet for Semaglutide
Be the first to share your experience.